Clinical Trial Update: A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Completed Phase 1 dose-escalation study of SGN-75 in CD70-positive non-Hodgkin lymphoma and renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Renal Cell Carcinoma

Drugs mentioned

• SGN-75

Snippet

Sponsor: Seagen Inc. | Conditions: Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED